Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brett Schlifka

Neurological Surgery Wellington, FL Doctor of Osteopathy

NPI 1790728913 CMS profile 216734

3319 State Road 7, Suite 313, Wellington, FL 33449

Open in the dashboard

General payments

$561,041

730 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brett Schlifka of Wellington, FL is reported in the CMS Open Payments database as having received $561,041 across 730 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32,727 59
2024 General $42,315 59
2023 General $92,878 101
2022 General $98,194 134
2021 General $86,521 111
2020 General $113,369 104
2019 General $95,037 162

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brett Schlifka
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Brett Schlifka were reported at $32,727. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Brett Schlifka Neurological Surgery median Middle half National median
2019 $95,037 $582 $138–$3,006 $163
2020 $113,369 $294 $76–$2,174 $114
2021 $86,521 $387 $105–$2,432 $132
2022 $98,194 $542 $139–$2,989 $149
2023 $92,878 $534 $145–$2,697 $160
2024 $42,315 $574 $155–$3,046 $164
2025 $32,727 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. The Institute of Musculoskeletal Science and Education $242,941 28 payments
  2. Stryker Corporation $65,310 45 payments
  3. Integrity Implants Inc $36,681 52 payments
  4. Baxter Healthcare $35,317 26 payments
  5. Medtronic USA, Inc. $21,557 73 payments
  6. Integrity Implants Inc. $19,943 12 payments
  7. NuVasive, Inc. $19,120 49 payments
  8. Spineart USA Inc $12,612 15 payments
  9. FloSpine LLC $11,636 8 payments
  10. Medtronic, Inc. $11,346 71 payments
  11. Other $84,578 351 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $280,381 36 payments
  2. Consulting Fee $170,597 84 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $37,218 7 payments
  4. Travel and Lodging $35,575 91 payments
  5. Food and Beverage $32,577 503 payments
  6. Education $3,619 6 payments
  7. Gift $575 2 payments
  8. Honoraria $500 1 payment
Products named General payments · program years 2019–2025
  1. Ti-Diagon $103,623 8 payments
  2. Orthros $103,623 8 payments
  3. Spira $82,387 8 payments
  4. Coveris $70,730 4 payments
  5. SPINEJACK $33,288 28 payments
  6. Linesider $30,440 19 payments
  7. AVAFLEX $28,975 7 payments
  8. AUTOPLEX $27,075 6 payments
  9. FlareHawk $21,777 12 payments
  10. ACTIFUSE $19,906 7 payments
  11. Other $201,926 519 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

811

Median for Neurosurgery: 83

Drug cost

$11,783

Median for Neurosurgery: $872

Branded share of claims

12%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 215 $6,071
Tizanidine Hcl Generic 163 $1,891
Gabapentin Generic 163 $1,552
Methylprednisolone Generic 77 $509
Pregabalin Generic 33 $476
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 27 $379
Methocarbamol Generic 27 $330
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 57 $279
Diclofenac Sodium Generic 13 $134
Cephalexin Generic 11 $82

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 132 billing codes

Paid by Medicare

$460,034

Medicare's payments for the services billed

Medicare patients

447

Average age 76

Services billed

1,672

256 women, 191 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 44%
Ischemic heart disease 41%
Osteoporosis 36%
Diabetes 34%
Chronic kidney disease 33%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kcentra
  • CSL Behring $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

730 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record